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Abstract:  24 
 25 
Objective: Acromegaly is a rare condition and there is often a long path to diagnosis for many 26 
patients.  We sought to explore patient’s perceptions and understanding of acromegaly, to examine 27 
the quality of communication and find gaps in the information provided at diagnosis.  28 
 29 
Design:  A prospective study using qualitative research methodology and grounded theory. A semi-30 
structured interview was conducted with 18 patients treated for acromegaly in a single tertiary centre 31 
and verbatim transcripts were thematically analysed for overarching themes. 32 
 33 
Results:  18 patients with acromegaly were interviewed. The mean age of participants was 52 (range 34 
30 – 72). Four overarching themes emerged; (1)Patients rely on online resources to understand 35 
acromegaly in the time between diagnosis and tertiary care clinic; (2) There is not enough support 36 
available for patients;  (3) Patients have a basic understanding of acromegaly and associated 37 
conditions, but the long term impact is underestimated; 4) Patients initially felt intimidated by the 38 
multidisciplinary team panel, but overall found it useful.  39 
 40 
Conclusion:  Acromegalic patients have a strong need for information at the point of initial diagnosis, 41 
in particular online resources and interaction with other experienced patients.  Wider dissemination 42 
of patient educational resources into primary and secondary care settings may improve overall 43 
patient satisfaction, treatment adherence and subsequent health care provider-patient relationships.   44 
 45 
 46 
 47 
 48 
 49 
Introduction   50 
Acromegaly, usually due to a benign pituitary adenoma, is a rare condition that has profound effects 51 
on all aspects of the body 1. Besides causing soft tissue growth, excess growth hormone is associated 52 
with co-morbidities such as hypertension, cardiomyopathy, diabetes and cancer 2. Acromegaly can be 53 
a challenging condition to identify and patients may often be diagnosed late 3.  By the time they 54 
attend clinic, patients may have already developed significant health problems, with significant 55 
impact on both quality of life and life expectancy 4, 5. Additionally, diagnostic delay often shapes 56 
patients’ attitudes to health care professionals, which impacts on the quality of communication and 57 
subsequent treatment adherence6, 7. 58 
 59 
In UK practice, often a secondary care endocrinologist or the primary care physician conveys the 60 
diagnosis to the patient before referral to a tertiary centre multidisciplinary team (MDT). This model is 61 
increasingly the gold standard of pituitary care in North America and Europe 8, 9. Therefore, it is 62 
anticipated that patients are informed of their diagnosis and given background information prior to 63 
their tertiary clinic appointment to discuss treatment options, including pituitary surgery, medical 64 
treatment with somatostatin analogues or radiotherapy. However, with an incidence of only 3.8 per 65 
million population 10, many primary care and secondary care physicians may lack experience with the 66 
condition.  Studies of the diagnostic pathway in acromegaly identify the point of diagnosis disclosure 67 
as critical in establishing patient- healthcare provider trust 6, 11.  Additionally acromegaly patients are 68 
often reluctant to share concerns or questions with healthcare providers at initial consultation6.  69 
However, there are few studies focusing on how information should be provided and how 70 
information resources are used by patients. 71 
 72 
Through qualitative research, this study aims to gain a better appreciation of patients’ experiences 73 
with the diagnosis of acromegaly.  We sought to identify gaps in patient information in the pathway 74 
to treatment, in order to improve future communication and to identify the support resources 75 
required and when they are needed.  76 
 77 
 78 
Patients and Methods 79 
 80 
Study design: 81 
A prospective qualitative study using a single semi-structured interview with patients diagnosed with 82 
acromegaly referred to a single regional tertiary pituitary centre.   83 
 84 
Participants: 85 
All patients aged over age 18 that had attended the pituitary multi-disciplinary pituitary clinic at the 86 
University Hospital of Wales with a biochemically confirmed diagnosis of acromegaly were invited for 87 
interview by telephone and provided with written information about the study.  Interviews were 88 
conducted via telephone or face to face. 89 
 90 
Data collection and analysis: 91 
 92 
Data collection and analysis in this qualitative study was based on grounded theory where ongoing 93 
data analysis leads to further questions to refine evolving theories12. As such interviews are 94 
conducted until no further themes emerge and saturation is reached13.  This allowed systematic 95 
generation and development of theories by being alert to emerging themes 14, prompting adding new 96 
questions to the interview guide. An initial interview guide was developed and subsequent questions 97 
added as new themes emerged during the study (Table  1). 98 
Each interview was recorded on tape and transcribed verbatim by the interviewer. Then, the 99 
transcripts were re-read to get an impression of the patients’ experiences. Thematic analysis was 100 
conducted first through open coding, to separate the data into segments which relate to one idea, 101 
then though axial coding, to combine similar ideas into overarching themes 15.  102 
Demographic data for each participant was collected including age, mode of presentation and region 103 
of presentation. 104 
 105 
Ethical considerations: 106 
This study was approved by the Cardiff and Vale University Health Board Specialist Services clinical 107 
board as a service evaluation and all participants provided verbal consent. 108 
 109 
Results 110 
25 patients were invited for interview.  18 patients were interviewed and data saturation was reached 111 
as the final interviews did not produce any new themes 16. The mean age of participants was 52 112 
(range 30 – 72); the mean age at diagnosis was 48 (range 26 – 72). Table 2 outlines the patient 113 
demographics. 11 patients (61%) were diagnosed by an endocrinologist in their local hospital, 1 114 
patient received the diagnosis from an orthopaedic surgeon after referral for carpal tunnel syndrome 115 
and 4 (22%) were diagnosed by their primary care physician. 116 
 117 
Thematic analysis 118 
Analysis of the interviews produced 4 overarching themes: 119 
 120 
1) Patients rely on online resources to understand acromegaly in the time between diagnosis and tertiary 121 
care clinic.  122 
Since acromegaly is a rare disease, patients may be entirely unaware of the condition and hence are 123 
surprised when they are given the diagnosis. Most patients felt they were not given enough 124 
information at diagnosis, which is usually delivered by their local endocrinologist or general practitioner 125 
(GP). Instead, they received the most information from the tertiary MDT clinic, as expected for a rare 126 
disorder. Only five patients reported that printed resources would have been useful at diagnosis.  127 
 128 
“It wasn’t brilliant. There’s not a real pamphlet and nothing that was explaining it. It was literally, ‘you 129 
got acromegaly’ ... most of it was done by myself, reading online about it.” 130 
 131 
“Possibly a leaflet about... explaining things. And as I say, what the pituitary gland does and the whole... 132 
some of the terminology ... of the various things that were going on.” 133 
 134 
Given delays between obtaining the diagnosis and attending the tertiary care clinic the greatest 135 
information need is between appointments.  All patients, except one, had searched online to learn more 136 
about acromegaly. All patients who searched online did so as soon as they heard about their diagnosis. 137 
However, many reported having to filter out what they read online as there is an overwhelming amount of 138 
information available and some can be distressing for patients to see.  139 
 140 
“When I  googled it and there was very outdated..... there was a man with a gigantic jaw.  When you 141 
google things, you can get lost.”  142 
 143 
Many patients used the National Health Service website Health A-Z (www.nhs.uk) to find information on 144 
acromegaly. Other resources which patients reported using are online groups such as on Facebook groups, 145 
forums, videos, podcasts and blogs. To find information, patients used google with the search terms 146 
‘Acromegaly’ or ‘Pituitary Tumour’. Five patients reported they found a number of North American 147 
resources online, for example, websites and video interviews, but few specific to the United Kingdom or 148 
their region.   Patient videos and websites from the UK may be more relevant and reassuring for the 149 
patients in this study.  150 
 151 
 152 
“I think the ones I remember were NHS UK, also the pituitary foundation and there seems to be a lot of 153 
academic stuff from America but if I remember rightly I started looking at sort of threads and help 154 
groups but it was just full of... it was the worst stories, you know, so I decided not to read about it 155 
anymore. I thought it would help but actually really didn’t, so I stuck with the facts, the clinical facts.” 156 
 157 
When asked if they had enough information to support treatment decisions, the majority of patients felt 158 
that initially they thought surgery was the only option, but learning about the procedure and alternative 159 
options helped put them at ease.  With information patients felt confident in the team treatment 160 
recommendation. 161 
 162 
2) There is not enough support available for patients 163 
All participants reported they would have liked to receive more support, as GPs are often unable to help 164 
with issues relating to acromegaly. 165 
 166 
“because they know you’re under specialists, they can’t help you because they just don’t know.”  167 
 168 
Patients find the ability to contact an endocrine nurse specialist for advice reassuring but this is often only 169 
available at the tertiary centre, following specialist referral.   170 
 171 
“there is an endocrine nurse centre there. Because I know the consultant will get back to you, but he 172 
very busy doing wards, doing the clinics, sometimes there is no one else that’s in, to offer any advice.” 173 
 174 
Importantly, patients expressed they would have liked to talk to treated patients, to get a better sense of 175 
what is happening and what they are about to go through. Meeting other people with acromegaly and 176 
reaching out to support groups could be an invaluable source of support for the patients.  177 
 178 
“Maybe meeting other people who has had it and have been cured for it... so you know what they’ve 179 
been through, what to expect. That would have been helpful.” 180 
 181 
Earlier signposting in the primary or secondary care setting to online resources and support groups in 182 
important in the patient pathway. 183 
 184 
“Maybe like the pituitary foundation, maybe it would have been best if I would... been told to... contact 185 
the pituitary foundation you know? To chat with them or the pituitary nurse...That would have been 186 
very good actually.”  187 
 188 
3) Patients have a basic understanding of acromegaly and associated conditions, but the long term 189 
impact is underestimated  190 
 191 
Despite feeling they lacked information, the majority of patients were aware acromegaly was associated 192 
with a growth hormone-secreting pituitary tumour and soft-tissue growth.  Almost all patients stated there 193 
was not enough information given about the long-term outlook of acromegaly, but they were aware of the 194 
hormone imbalance and the physical changes that would occur if left untreated. The knowledge of other 195 
long-term complications of acromegaly was variable, but the majority of patients were able to name 196 
several.  197 
 198 
“All I know it is ... it causes the growth hormones to... grow, which umm... make my fingers swell up 199 
and... and my feet ... uhh, and obviously part of my face” 200 
 201 
“If it’s not treated, it can cause shortening of life, umm, you heart can grow and your diabetes could 202 
get worse, you can have strokes, you can have a risk of heart attacks...” 203 
 204 
“Well, the heart problems, the diabetes or the bowel problems, I don’t know any more than that.” 205 
 206 
In the beginning, patients assumed that they would be cured after the surgery and would be normal again. 207 
They may not have realised that they will still require follow up for recurrence, and may still suffer from 208 
symptoms after surgery, for example, headaches and fatigue.  209 
 210 
“It’s just, I can’t see an end to it, I don’t feel like there will ever be an end to it. You still gotta be 211 
checked after. But I can’t see a light at the end of the tunnel...” 212 
 213 
“It wasn’t explained that this might not be the end of it, you might need to have another operation and 214 
it might not... I think I was naïve a little bit then, I hadn’t realised that.” 215 
 216 
Acromegaly had a varied long term impact on patients, 50% felt the disease had not greatly impacted their 217 
lives and were able to get back to normal following surgery.  However, for the remainder the experience 218 
was life-changing and they still struggle with work and relationships despite successful treatment.  Many 219 
patients reported ongoing problems with depression and anxiety. 220 
 221 
4) Patients initially felt intimidated by the tertiary multidisciplinary clinic, but overall found it useful.  222 
 223 
Patients reported being given minimal warning before attending the MDT of the nature of the clinic. 224 
Therefore some of them felt shocked to see a large group of clinicians and nurses in the room. They were 225 
put at ease quickly and have generally benefitted from the team meeting.  226 
 227 
“It was useful I guess, you had the input of a lot of different specialists at the same time, so yeah. It 228 
was intimidating but it was also reassuring to know that there was... more than one person looking at 229 
your case.”  230 
 231 
“Well only when you go in and you see seven people sitting there and they’re all, you know, professors 232 
and consultants... they were absolutely fine... but it’s a bit intimidating just to see that panel...”  233 
 234 
Patients benefit from meeting the whole team that will guide them through their treatment and follow-up, 235 
however providing information prior to the clinic on the team members and roles would be useful. 236 
 237 
Discussion 238 
 239 
Using qualitative research methods to explore the needs of patients newly diagnosed with acromegaly in a 240 
primary or secondary care setting demonstrates the need for high-quality, relevant online resources and 241 
local support networks. The internet is being used increasingly by patients to research their health 242 
conditions 17, 18. This has been shown to affect the patient’s beliefs and potentially change their decision 243 
about treatment 19. Our study shows that patients diagnosed with acromegaly turn to online resources 244 
early after initial diagnosis to learn more about their condition.  Interestingly, patients appear much more 245 
reliant on online information and patient-to-patient interaction than the traditional printed information 246 
leaflet. 247 
 248 
However, patients may be overwhelmed by what they might find online and, quality of information on the 249 
internet may be substandard 20. Our cohort highlighted the importance of online materials and groups 250 
being regionally specific to them.  Ideally, patients would like to be provided with reliable online resources 251 
at initial diagnosis and guidance to help them make sense of the information 21. In a similar study by Gurel 252 
et al 6, 19 patients participated in online and face-to-face interviews aimed at understanding the impact of 253 
a diagnosis of acromegaly.  They demonstrated a strong desire for education about the disease at 254 
diagnosis, noting the diagnosis seemed to ‘fuel a thirst for knowledge’ in all participants 6. As in our study, 255 
participants emphasized the need for patient-patient interaction as part of their quest for knowledge and 256 
a desire to take control of their disease, highlighting the need for access to support groups.  Plunkett and 257 
Barken 11 suggest strategies to facilitate the patient-healthcare professional relationship throughout the 258 
treatment pathway and highlight the provision of educational and emotional support resources at the 259 
initial diagnosis meeting.  Such resources include The Pituitary Foundation (www.pituitary.org.uk). In 260 
particular, their support groups and peer support programme may address the patients’ needs to speak 261 
with more experienced acromegalic patients and encourages the exchange of health information 18, 20, 21. 262 
Video presentations by similar patients, such as the UK acromegaly meetup, could be helpful for newly 263 
diagnosed patients (UK Acromegaly Meetup 2017: Patient stories - Rachel and Carolyn.  264 
https://youtu.be/llqhT-FheMA , accessed 27.03.20). 265 
 Internationally The Pituitary Society (www.pituitary-society.org), Acromunity.com and 266 
Acromegalycommunity.com provide resources and access to support groups.  However, in a study to 267 
assess communication practices among endocrinologists, Polanco-Briceno et al22 reported only 14% of 268 
respondents routinely recommended educational resources or programs to patients and only 44% were 269 
aware of these resources.  Additionally, most physicians in the study did not have dedicated nurse to 270 
discuss these topics with patients. 271 
 272 
Qualitative research is becoming more popular in surgical and medical practice 23, as it can provide an 273 
insight into the social aspects of being treated for a disease from the patient’s perspective 24. To date most 274 
qualitative research in acromegaly focuses on diagnostic delay and treatment adherence 7, 25.  A study by 275 
Sibeoni et al 7 conducted with 18 participants  revealed the lack of awareness in the medical community as 276 
a significant factor for a diagnostic delay. Most patients had interactions with many healthcare 277 
professionals who did not recognise or believe the symptoms being reported, which in turn drives a thirst 278 
for knowledge at diagnosis and shapes subsequent attitudes towards doctors 6.  Sibeoni et al7 also reveal 279 
the psychosocial elements of a delayed diagnosis of acromegaly and suggest that endocrinologists should 280 
be involved in addressing the psychological impact of the condition together with support of mental 281 
wellbeing.  282 
 283 
A study with a focus group of 6  acromegalic patients to explore patient perceptions of disease impact 284 
presented a wide variety of causes for a reduced quality of life in patients with acromegaly 26. Some issues 285 
discussed in the focus group correlate with those reported by patients in our study. These include fatigue, 286 
mental health problems and worries about fertility 26.  These issues are not covered in available disease 287 
specific quality of life questionnaires. In their study, they advise clinicians to be more aware of these 288 
problems in order that appropriate support may be provided 26. It is clear that patients focus initially on 289 
the immediate treatment and resolution of symptoms such as fatigue, headaches and joint pain, but pay 290 
little attention to the potential long term implications or need for future multimodal therapy 6.  When and 291 
how patients should receive this information and how they will process it is not clear.  However our study 292 
and that of Gurel et al 6 suggest this is most likely to have an impact when discussed in a patient-to-patient 293 
forum.  294 
 295 
Despite a clear benefit from a multidisciplinary team approach to the management of pituitary disease 9, 27, 296 
patients find the experience intimidating.  Although not all centres will adopt a joint MDT clinic with 297 
multiple clinicians; in our practice we find it beneficial to facilitate discussion between the patient, 298 
endocrinologist, surgeon and radiation oncologist to explore all treatment options.  Prior contact from a 299 
specialist nurse or written information detailing the team members and their roles may help ease some 300 
anxiety and improve subsequent treatment adherence and overall satisfaction 11.  301 
 302 
Overall, despite increasing awareness of acromegaly and a recent reduction in the delay to diagnosis 4, 303 
most patients are diagnosed in non-specialist centres with limited access to specific support resources.  304 
There is a need for clear signposting to up-to-date online resources that patients feel is relevant to them 305 
both factually and geographically.  Our study demonstrates this should occur prior to attendance at the 306 
specialist tertiary centre together with a need for supporting education on acromegaly in primary and 307 
secondary care. 308 
 309 
Limitations:  310 
 311 
This study involves patients from a single centre and results drawn from the study may not apply to other 312 
patient groups and/or internationally. Nevertheless, conclusions drawn from this study may still be 313 
relevant for other centres to better appreciate the needs of patients with acromegaly. In any qualitative 314 
study the interviewer’s ideas and assumptions can bias the outcome; however, the semi-structured format 315 
and open questions should have allowed the patients to speak freely about their experience and concerns. 316 
 317 
Conclusion 318 
The study demonstrates some of the challenges faced by patients with acromegaly and gives us an insight 319 
into knowledge of their condition and what information and support they require.   It highlights a need for 320 
better communication with patients as well as guidance for online searching.   There is a clear need for the 321 
provision of information at the point of initial diagnosis in whatever care setting that may be made.  The 322 
wider education and dissemination of appropriate online resources will improve subsequent health care 323 
provider-patient communication and ultimately improve treatment satisfaction and quality of life. 324 
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